Fibrocell launches anti-inflammatory pact with Intrexon; Halozyme inks $150M credit deal; Ohio biotech plots HQ move to San Diego

> Exton, PA-based Fibrocell Science ($FCSC) is teaming up with Intrexon ($XON) to develop genetically engineered fibroblasts to treat inflammatory conditions, with a special focus on arthritis. Fibrocell is handing over a $10 million tech access fee to get the partnership launched, with up to $52.5 million in development and commercial milestones for each new product that gets through to an approval. Fibrocell will also foot the bill for R&D. Release

> Halozyme Therapeutics ($HALO) inked a $150 million credit agreement after pledging royalties from its Enhanze products. Release

> The Ohio biotech Biosortia Pharmaceuticals is moving its HQ into J&J's ($JNJ) accelerator in San Diego after raising $500,000. Story

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.